<DOC>
	<DOCNO>NCT01126177</DOCNO>
	<brief_summary>When people asthma get respiratory virus cold flu often increase asthma symptom . The investigator test study medication find prevent virus spread nose lung . SNG001 contain Interferon-beta occurs naturally body . In study , SNG001 give nebuliser .</brief_summary>
	<brief_title>Comparing Efficacy Safety Inhaled SNG001 Placebo</brief_title>
	<detailed_description>The study consist Pre-Treatment Phase subject potentially eligible Treatment Phase recruit . Subjects remain Pre-Treatment Phase experience respiratory virus symptom time screen eligibility entry Treatment Phase . If eligible , subject randomise 1:1 receive SNG001 placebo daily 14 day . Doses deliver CE mark breath actuate nebuliser ( I-neb Philips Respironics ) . Subjects assess change change respiratory virus symptom asthma symptom home use text message system , via telephone questionnaire . Lung function measure home subject ( PEFR ) clinic . Efficacy safety monitor least 30 day post treatment .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>1 . Male female age 18 65 year age time screen . 2 . Symptoms asthma least 2 year pri Screening Visit , confirm medical history : 1 . ≥12 % 200mL bronchodilator reversibility screen document past , OR , 2. evidence bronchial hyperresponsiveness screen document past , OR , 3. document hospital admission ( include Accident Emergency admission ) asthma since age 18 , OR . 4. document evidence attend GP surgery , outofhours clinic ( alternative health care provider ) worsen asthma symptom , since age 18 3 . Must answer `` Yes‟ question `` Does cold make asthma bad ? '' 4 . To least one asthma exacerbation suspect caused respiratory virus last 24 month require use oral steroid and/or additional treatment antibiotic one occasion . 5 . Must take regular inhaled corticosteroid . 6 . Prebronchodilator FEV1 ≥ 40 % predict screening . 7 . Postbronchodilator FEV1 ≥ 50 % predict screening . 8 . Provide write informed consent . 9 . Females childbearing potential must use medically acceptable adequate form birth control agree maintain usage throughout duration four week post Treatment Phase study . 10 . Motivation ( Investigator‟s opinion ) complete study visit , ability communicate well Investigator capable understanding nature research treatment include risk benefit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>asthma</keyword>
</DOC>